Ibrutinib (Imbruvica) for relapsed and refractory marginal zone lymphoma – second or subsequent line
NIHR HSRIC

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
Marginal zone lymphoma is a type of cancer which usually develops very slowly. In people with marginal zone lymphoma, the body makes too many white blood cells called B-lymphocytes. These lymphocytes are abnormal and do not work properly and build up in different parts of the body such as the gut, salivary glands, eyes, spleen, and lymph nodes. Ibrutinib is a new type of drug for patients with marginal zone lymphoma given as a tablet once a day. Some studies have suggested ibrutinib may be helpful for people whose first treatment has failed and whose disease has spread. If ibrutinib is licensed for use in the UK, it could be a new treatment option for patients with marginal zone lymphoma that may reduce symptoms of the disease and increase survival.

Final publication URL
http://www.hsric.nihr.ac.uk/topics/ibrutinib-imbruvica-for-relapsed-and-refractory-marginal-zone-lymphoma-second-or-subsequent-line/

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasm Recurrence, Local; Pyrazoles; Pyrimidines

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk

AccessionNumber
32016000440

Date abstract record published
08/03/2016